IN THE CLAIMS

This listing of claims replaces all prior versions, and listings, in this application.

1. (original) A composition comprising a conjugate of a photosensitiser and a bacteriophage.

2. (original) A composition according to claim 1, wherein the bacteriophage is a staphylococcal bacteriophage.

3. (previously presented) A composition according to claim 1, wherein the photosensitiser is covalently linked to the bacteriophage.

4. (currently amended) A composition according to claim 1, wherein the photosensitiser is ~~chosen~~ selected from the group consisting of porphyrins, ~~Porphyrins,~~ phthalocyanines, chlorins, bacteriochlorins, phenothiaziniums, phenazines, acridines, texaphyrins, cyanines, anthracyclins, pheophorbides, sapphyrins, fullerene, halogenated xanthenes, perylenequinonoid pigments, gilvocarcins, terthiophenes, benzophenanthridines, psoralens and riboflavin.

5. (original) A composition according to claim 4, wherein the photosensitiser is tin (IV) chlorin e6 (SnCe6).

6. (currently amended) A composition according to claim 1, wherein the bacteriophage is ~~chosen~~ selected from the group consisting of phage 53, 75, 79, 80, 83, Φ11, Φ12, Φ13, Φ147, ΦMR11, 48, 71, Φ812, SK311, Φ131, SB-I, U16, C_1, SF370.1, SP24, SFL, A1, ATCC 12202-B1, f304L, Φ304S, Φ15, Φ16, 782, P1clr100KM, P1, T1, T3, T4, T7 MS2, P1, M13, UNL-1, ACQ, UT1, tbalD3, E79, F8, pf20 B3, F116, G101, B86, T7M, ACq, UT1, BLB, PP7, ATCC 29399-B1 and B40-8.

7. (original) A composition according to claim 6, wherein the bacteriophage is phage 75 or phage Φ11.

8. (previously presented) A composition according to claim 1, wherein the concentration of the photosensitiser is from 0.01 to 200 μg/ml.

9. (previously presented) A composition according to claim 1, wherein the concentration of the bacteriophage is from $1x10^5$ to $1x10^{10}$ pfu/ml.

10. (currently amended) A composition according to claim 1, which further comprises a source of Ca^{2+} ions~~, preferably calcium chloride~~.

11. (previously presented) A composition according to claim 1, in the form of a solution n a pharmaceutically acceptable carrier.

12. (previously presented) A composition according to claim 1, wherein the composition further comprises one or more of a buffer, salt, antioxidant, preservative, gelling agent or remineralisation agent.

13. (previously presented) A method of killing bacteria, comprising

(a) contacting an area to be treated with a composition according to claim 1, such that any bacteria present bind to the photosensitiser-bacteriophage conjugate; and

(b) irradiating the area with light at a wavelength absorbed by the photosensitiser.

14. (currently amended) A method according to claim 13, wherein the bacteria are staphylococcus, particularly MRSA, EMRSA VRSA, hetero-VRSA or CA-MRSA.

15. (previously presented) A method according to claim 13, wherein the light is laser light or white light.

16. (original) A method according to claim 15, wherein the laser light is from a helium neon gas laser.

17. (previously presented) A method according to claim 15, wherein the laser light has a wavelength of from 200 to 1060 nm.

18. (previously presented) A method according to claim 15, wherein the laser has a power of from 1 to 100 mW and a beam diameter of from 1 to 10 mm.

19. (previously presented) A method according to claim 18, wherein the light dose of laser irradiation is from 5 to 333 Jcm^{-2}.

20. (previously presented) A method according to claim 15, wherein the light dose of white light is from 0.01 to 100 J/cm^2.

21. (previously presented) A method according to claim 15, wherein the duration of irradiation is form one second to 15 minutes.

22. (previously presented) A method according to claim 13, wherein the composition is present in or on the area to be treated at a concentration of from 0.00001 to 1% w/v.

23. (currently amended) ~~Use of a composition according to claim 1,~~ A method for treatment of the human or animal body, comprising administering an effective amount of a composition according to claim 1.

24. (currently amended) ~~Use of a composition according to claim 1, in the manufacture of a medicament~~ A method for treatment of bacterial infection, comprising administering an effective amount of a composition according to claim 1.

25. (currently amended) [[Use]] A method according to claim 24, wherein the bacterial infection is *S. aureus*~~, particularly MRSA, EMRSA, VRSA, hetero-VRSA or CAMRSA~~.

26. (currently amended) [[Use of]] A method of photodynamic therapy (PDT), wherein a bacteriophage is used as a targeting agent~~ in photodynamic therapy (PDT)~~.

27. (currently amended) [[Use]] A method according to claim 26, wherein the bacteriophage is a staphylococcal phage.

Claims 28-30 (canceled)

31. (new) A composition according to claim 1, which further comprises calcium chloride.

32. (new) A method according to claim 13, wherein the bacteria are MRSA, EMRSA VRSA, hetero-VRSA or CA-MRSA.

33. (new) A method according to claim 24, wherein the bacterial infection is MRSA, EMRSA VRSA, hetero-VRSA or CA-MRSA.